Kelley Timothy
Manag Care. 2017 Mar;26(3):28-30.
No one knows how much of an effect biosimilars will have on oncology expenditures. Pricing and market share are in a large, opaque "to be determined" cloud. But there's certainly potential for a major impact that could lower oncology expenditures by millions, if not billions.
没有人知道生物类似药会对肿瘤学支出产生多大影响。价格和市场份额处于一个巨大的、不透明的“有待确定”的迷雾之中。但肯定有产生重大影响的可能性，这可能会使肿瘤学支出降低数百万美元，如果不是数十亿美元的话。
